- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02751125
Reconstruction of Jaw Bone Using Mesenchymal Stem Cells
Jaw Bone Reconstruction Using a Combination of Autologous Mesenchymal Stem Cells and Biomaterial Prior to Dental Implant Placement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eleven patients presenting with the need of an implant retained restoration in the posterior mandibula and an alveolar ridge of maximum 4.5 mm width.
A clinical examination, x- rays and Cone Beam CT(CBCT) are accessed. A sample of the patients' bone marrow is extracted from the posterior alveolar ridge, immediately shipped to the collaborating good clinical practice (GCP) cell laboratory for cell expansion, and returned after 21 days. The stem cells mixed with Bi Calcium Phosphate (BCP) are then used to augment the alveolar ridge. The material is covered with a titanium reinforced membrane before closure of the site. After four to six months a bone biopsy is performed and implants are installed in the regenerated bone.
The patient will be followed after 1, 2, 3, and 5 years where implant stability will be assessed. Furthermore the new formed bone will be clinically and radiologically assessed at the same time.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hordaland
-
Bergen, Hordaland, Norway, 5008
- Institute of Clinical Dentistry, University of Bergen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Patients presenting with an indication for an implant and wanting implant-borne prosthetic restoration.
- Patients presenting with lateral or vertical bone loss (focusing lateral bone loss) of the mandible behind the canine tooth.
- Lateral (width 5 mm or less) bone loss preventing the insertion of an implant without prior bone augmentation.
- Endentate for more than 6 months in the region requiring reconstruction.
- Endentate concerning at least 2 missing teeth in the region requiring reconstruction.
- Absence of clinical signs of infection in the region requiring reconstruction.
- Patients presenting with good dental hygiene (subjective criteria)
- Patients not presenting with any major oral pathologies.
- Dental crest size less than 5 mm.
General criteria:
- Adult patients over 18 and under 80 years of age.
- Patients in good general health presenting with a complete blood count and renal and hepatic function values within normal limits (confirmed by local laboratory tests).
- Patients with the capacity to understand medical information and give their informed consent.
Exclusion Criteria:
ocal criteria:
- Patients presenting with clinical or radiological signs of bone infection (acute or chronic osteomyelitis).
- Residual dentition close to the area requiring reconstruction with untreated endodontic disorder (apical granuloma or apical cyst).
- Untreated oral infection (cellulitis, periodontitis).
- Patients with poor hygiene (subjective criteria).
- Surgical procedure undertaken in the area requiring reconstruction less than 6 months prior to the bone graft.
- History of malignant tumors of the upper airways / digestive tract or of the jaw.
- History of or scheduled cervico-facial radiation therapy.
General criteria:
- The patient suffers from any serious coagulation disorders that could require substitution therapy
- The patient is receiving VKA therapy, which should be adjusted if necessary so that the INR does not exceed 2.5
- The patient has history of allergy to iodine or to local anesthetics(sulfites, etc.)., or a history of hematoma, or hemorrhage or blood coagulation disorders
- The patient has received localized iliac crest radiotherapy contraindicating withdrawal from the irradiated site
- The patient has major skin lesions or diseases.
- Patients presenting with bone metabolism disorders: hypophosphatemia, primary parathyroid osteitis or that is secondary to chronic renal insufficiency or osteomalacia, Paget's disease, vitamin D-related disorders, osteoporosis.
- Pregnant or breastfeeding women or women not using effective contraception if they are of childbearing age.
- Patients presenting with cancerous disorders (carcinoma, sarcoma, leukemia, lymphoma) or psychiatric disorders or with uncontrolled systemic diseases (diabetes, hypertension), or chronic renal disease.
- Severe bruxism.
- History of chemotherapy.
- Smoking or alcohol addiction. Occasional consumption of alcohol and/or smoking will be noted in the case report form.
- Patients with an ASA score of 0 or 1, incapable of tolerating general anesthesia.
- Immunosuppression
- Body mass index outside the normal range, particularly >30 because of increased surgical risk at the time of BM harvesting from the iliac crest.
- Risk of remote infection (orthopedic prosthesis implanted in the previous 6 months, patients presenting with a high risk of infective endocarditis, presence of pulmonary arteriovenous shunt, etc.).
- HIV, HTLV and/or syphilis seropositivity.
- Hepatitis B or C infection.
- Active autoimmune disease.
- History of immunosuppressant treatment or bone marrow treatment.
- Administration of treatment interfering with bone metabolism.
- Patients requiring antibiotic prophylaxis before any dental procedure
- Patients reticent to undergo dental care or periodontal treatment
- Concomitant treatments: history of treatment or current treatment with bisphosphonates, long term corticosteroid treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Augmentation of new alveolar bone
Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
|
Augmentation of narrow alveolar ridge with BCP and MSC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.
Time Frame: Four to six months post augmentation
|
CBCT
|
Four to six months post augmentation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implant stability
Time Frame: 12 months
|
Implant stability measurement using the Ostell system
|
12 months
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 5 years
|
Safety of MSC in patients.
Adverse events
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cecilie Gjerde, DDS, University of Bergen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-003139-50
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Atrophy
-
University of Sao PauloUnknownDisorder of Maxillary Sinus | Accessory; Bone | Bone Atrophy
-
Central Clinical Hospital w/Outpatient Health Center...UnknownAlveolar Bone Loss | Alveolar Bone Atrophy | Partially Edentulous MaxillaRussian Federation
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Cairo UniversityRecruiting
-
University of BergenAssistance Publique - Hôpitaux de Paris; University of Aarhus; Universidad Complutense... and other collaboratorsRecruitingAlveolar Bone AtrophyDenmark, France, Norway, Spain
-
University of Sao PauloCompletedBone Resorption | Alveolar Bone AtrophyBrazil
-
International Piezosurgery AcademyWithdrawn
-
International Piezosurgery AcademyCompleted
-
Hussien Amer ElkadyUnknown
-
Pontificia Universidade Católica do Rio Grande...KU Leuven; ITI International Team for Implantology, Switzerland; Rio Grande do...Not yet recruitingAlveolar Bone Loss | Bone Loss, Alveolar | Grafting Bone | Alveolar Bone Atrophy | Bone Loss, OsteoclasticBrazil
Clinical Trials on BCP with autologous mesenchymal stem cells (MSC).
-
Dimitrios KarussisCompletedMultiple Sclerosis (MS)Israel
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
Mayo ClinicRecruiting
-
Mayo ClinicCompletedAtherosclerotic Renal Artery Stenosis | Ischemic Nephropathy | Renovascular HypertensionUnited States
-
Hadassah Medical OrganizationCompleted
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
University of LiegeTerminated
-
National Institute of Blood and Marrow Transplant...Armed Forces Institute of Regenerative MedicineCompletedSpinal Cord InjuryPakistan
-
Rigshospitalet, DenmarkCompletedChronic Ischemic Heart DiseaseDenmark